

United States Senate  
WASHINGTON, DC 20510-3203

March 16, 2023

Paul Hudson  
Chief Executive Officer  
Sanofi  
46 Avenue de la Grande Armée  
75017 Paris, France

Dear Mr. Hudson:

The exponential spike in the cost of insulin is one of the most unjust health care trends of the past few decades. Its skyrocketing price has led to heart-wrenching scenarios where people are forced into the unconscionable position of choosing between the medicine they need to live, food on the table, or a roof over their head. In a country as prosperous as America, health care should be a fundamental right, and no person should have to decide between taking care of their health and making ends meet.

Democrats prioritized and successfully passed legislation last Congress making insulin more affordable, including a \$35 monthly co-pay cap for seniors on Medicare. Unfortunately, there was not bipartisan support for capping co-pays for Americans under the age of 65, but I remain committed to finding a bipartisan path forward on that vital policy.

In the interim, as you undoubtedly know, some insulin manufacturers have in recent weeks heeded my call to lower their prices and make insulin more universally affordable. Eli Lilly dropped its list price for insulin by 70 percent, while also voluntarily capping patient costs at \$35 per month. Novo Nordisk shortly followed suit, dropping its list price by 75 percent.

Sanofi, along with Eli Lilly and Novo Nordisk, represent roughly 90 percent of the global insulin market. Of the big three insulin manufacturers, Sanofi remains the only one not to reduce its insulin prices.

I urge you to expediently follow in the footsteps of the other companies and lower your insulin prices in a similar manner. Doing so will save lives and move our country one step closer to ending our insulin affordability crisis.

Sincerely,



Charles E. Schumer  
United States Senator